| Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations H Young, R Baum, U Cremerius, K Herholz, O Hoekstra, AA Lammertsma, ... European journal of cancer 35 (13), 1773-1782, 1999 | 1949 | 1999 |
| Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care SR Cherry, T Jones, JS Karp, J Qi, WW Moses, RD Badawi Journal of Nuclear Medicine 59 (1), 3-12, 2018 | 622 | 2018 |
| The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, ... British journal of cancer 92 (9), 1599-1610, 2005 | 583 | 2005 |
| First human imaging studies with the EXPLORER total-body PET scanner RD Badawi, H Shi, P Hu, S Chen, T Xu, PM Price, Y Ding, BA Spencer, ... Journal of Nuclear Medicine 60 (3), 299-303, 2019 | 582 | 2019 |
| Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases P Price, PJ Hoskin, D Easton, D Austin, SG Palmer, JR Yarnold Radiotherapy and Oncology 6 (4), 247-255, 1986 | 567 | 1986 |
| Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers SC Winter, FM Buffa, P Silva, C Miller, HR Valentine, H Turley, KA Shah, ... Cancer research 67 (7), 3441-3449, 2007 | 407 | 2007 |
| Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results GJS Rustin, SM Galbraith, H Anderson, M Stratford, LK Folkes, L Sena, ... Journal of clinical oncology 21 (15), 2815-2822, 2003 | 384 | 2003 |
| 3′-deoxy-3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography H Barthel, MC Cleij, DR Collingridge, OC Hutchinson, S Osman, Q He, ... Cancer research 63 (13), 3791-3798, 2003 | 370 | 2003 |
| Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation P Price, TJ McMillan Cancer research 50 (5), 1392-1396, 1990 | 358 | 1990 |
| A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain PJ Hoskin, P Price, D Easton, J Regan, D Austin, S Palmer, JR Yarnold Radiotherapy and Oncology 23 (2), 74-78, 1992 | 327 | 1992 |
| Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate HL Anderson, JT Yap, MP Miller, A Robbins, T Jones, PM Price Journal of Clinical Oncology 21 (15), 2823-2830, 2003 | 251 | 2003 |
| X-ray volumetric imaging in image-guided radiotherapy: the new standard in on-treatment imaging CA McBain, AM Henry, J Sykes, A Amer, T Marchant, CM Moore, J Davies, ... International Journal of Radiation Oncology* Biology* Physics 64 (2), 625-634, 2006 | 245 | 2006 |
| Total-body imaging: transforming the role of positron emission tomography SR Cherry, RD Badawi, JS Karp, WW Moses, P Price, T Jones Science translational medicine 9 (381), eaaf6169, 2017 | 233 | 2017 |
| Tumour inoculation during laparoscopy N O'Rourke, PM Price, S Kelly, K Sikora, L Fligelstone, M Rhodes, D Flook, ... The Lancet 342 (8867), 368-369, 1993 | 217 | 1993 |
| Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies P Workman, EO Aboagye, YL Chung, JR Griffiths, R Hart, MO Leach, ... Journal of the National Cancer Institute 98 (9), 580-598, 2006 | 216 | 2006 |
| The development of [124I] iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography DR Collingridge, VA Carroll, M Glaser, EO Aboagye, S Osman, ... Cancer Research 62 (20), 5912-5919, 2002 | 194 | 2002 |
| Hypoxia-inducible factor 1α expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of … GJ Hutchison, HR Valentine, JA Loncaster, SE Davidson, RD Hunter, ... Clinical cancer research 10 (24), 8405-8412, 2004 | 192 | 2004 |
| A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients L Rosso, CS Brock, JM Gallo, A Saleem, PM Price, FE Turkheimer, ... Cancer research 69 (1), 120-127, 2009 | 189 | 2009 |
| The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels H Barthel, M Perumal, J Latigo, Q He, F Brady, SK Luthra, PM Price, ... European journal of nuclear medicine and molecular imaging 32, 257-263, 2005 | 168 | 2005 |
| Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancer BA Gusterson, LG Machin, WJ Gullick, NM Gibbs, TJ Powles, P Price, ... International journal of cancer 42 (6), 842-845, 1988 | 164 | 1988 |
